Market Overview

Benzinga's Top Downgrades

Related NVS
Drug ETFs Attractive Buys On Pullback
US Stock Futures Signal Lower Start On Wall Street
Bayer Buys Merck Consumer Care Unit (Fox Business)
Related ZIOP
ZIOPHARM Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update
Mid-Morning Market Update: Markets Gain On Jobs Data; VeriFone Earnings Beat Estimates

Analysts at Deutsche Bank downgraded Novartis AG (NYSE: NVS) from “buy” to “hold.” Novartis' shares closed at $63.20 yesterday. Novartis' trailing-twelve-month ROA is 6.24%.

Analysts at Jefferies downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from “buy” to “hold.” ZIOPHARM's shares closed at $4.44 yesterday. ZIOPHARM's trailing-twelve-month ROE is -110.59%.

Analysts at Wells Fargo downgraded Stifel Financial (NYSE: SF) from “market perform” to “underperform.” Stifel Financial's shares closed at $31.45 yesterday. Stifel Financial's PEG ratio is 0.81.

Brean Capital downgraded IDEX (NYSE: IEX) from “buy” to “hold.” IDEX's shares closed at $45.98 yesterday. IDEX's trailing-twelve-month profit margin is 10.50%.

Latest Ratings for NVS

DateFirmActionFromTo
May 2014JefferiesUpgradesHoldBuy
Apr 2014NatixisDowngradesBuyNeutral
Mar 2014Morgan StanleyInitiates Coverage onUnderweight

View More Analyst Ratings for NVS
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (IEX + NVS)

Around the Web, We're Loving...

Get Benzinga's Newsletters